- Home
- XLO vs ATRA Comparison
XLO vs ATRA Comparison
Compare XLO & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XLO
- ATRA
- Stock Information
- Founded
- XLO 2016
- ATRA 2012
- Country
- XLO United States
- ATRA United States
- Employees
- XLO N/A
- ATRA N/A
- Industry
- XLO Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XLO Health Care
- ATRA Health Care
- Exchange
- XLO Nasdaq
- ATRA Nasdaq
- Market Cap
- XLO 42.2M
- ATRA 40.1M
- IPO Year
- XLO 2021
- ATRA 2014
- Fundamental
- Price
- XLO $0.69
- ATRA $7.94
- Analyst Decision
- XLO Buy
- ATRA Buy
- Analyst Count
- XLO 1
- ATRA 5
- Target Price
- XLO $4.00
- ATRA $17.75
- AVG Volume (30 Days)
- XLO 950.0K
- ATRA 61.5K
- Earning Date
- XLO 08-07-2025
- ATRA 08-11-2025
- Dividend Yield
- XLO N/A
- ATRA N/A
- EPS Growth
- XLO N/A
- ATRA N/A
- EPS
- XLO N/A
- ATRA N/A
- Revenue
- XLO $9,274,000.00
- ATRA $199,732,000.00
- Revenue This Year
- XLO $300.08
- ATRA N/A
- Revenue Next Year
- XLO $1.87
- ATRA N/A
- P/E Ratio
- XLO N/A
- ATRA N/A
- Revenue Growth
- XLO N/A
- ATRA 475.53
- 52 Week Low
- XLO $0.62
- ATRA $5.01
- 52 Week High
- XLO $1.70
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- XLO 42.49
- ATRA 48.77
- Support Level
- XLO $0.65
- ATRA $7.74
- Resistance Level
- XLO $0.70
- ATRA $9.00
- Average True Range (ATR)
- XLO 0.04
- ATRA 0.54
- MACD
- XLO -0.01
- ATRA -0.12
- Stochastic Oscillator
- XLO 19.51
- ATRA 19.79
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).